Skip to Content
Merck

Hyperinsulinism in tyrosinaemia type I.

Journal of inherited metabolic disease (2005-05-07)
U Baumann, M A Preece, A Green, D A Kelly, P J McKiernan
ABSTRACT

Tyrosinaemia type I (TT I) (McKusick 276700) is a heterogeneous disorder with a broad spectrum of clinical phenotypes. Although histological abnormalities of the pancreas are well recognized, there are only incidental reports of pancreatic dysfunction manifested as insulin-dependent diabetes mellitus. We report three subjects with TT I and acute liver dysfunction who had hyperinsulinism in early infancy. Hypoglycaemia persisted despite dietary treatment and one patient had inadequate lipolysis at the time of hypoglycaemia. All three patients were successfully treated with diazoxide (10 mg/kg per day) and chlorthiazide (35 mg/kg per day) and treatment was gradually withdrawn after 9, 13 and 34 months, respectively. The mechanism of pancreatic dysfunction in TT I is unknown but may be related to the toxic metabolites that accumulate in this condition. We conclude that hyperinsulinism is not a rare complication in TT I. In patients with persistent hypoglycaemia, C-peptide should always be measured. Treatment with diazoxide and chlorthiazide is highly effective, appears to be safe, and does not need to be continued lifelong.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Chlorothiazide, thiazide diuretic
Chlorothiazide, European Pharmacopoeia (EP) Reference Standard
Supelco
Chlorothiazide, Pharmaceutical Secondary Standard; Certified Reference Material